Good DREAMM-1 Data Keeps GSK On Track For Multiple Myeloma Filing This Year
Executive Summary
Confirmation of good trial data for GSK's promising anti-BCMA antibody-drug conjugate GSK2857916 in multiple myeloma patients keeps it in the running for eventual regulatory approval by 2020 - but it faces a formidable field of emerging rival therapies.
You may also be interested in...
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
GSK Files Its BCMA Drug In Multiple Myeloma
GSK has filed its anti-BCMA agent with the FDA after full Phase II DREAMM-2 data showed an overall response rate of 31% in patients with heavily pre-treated multiple myeloma.
DREAMM-2 Put GSK’s BCMA Drug In Pole Position In Multiple Myeloma
The DREAMM-2 trial of the antibody-drug conjugate belantamab mafodotin in relapsed/refractory multiple myeloma patients has hit its primary endpoint, giving GSK a chance to file for approval before its BCMA rivals.